Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone and NAC for Post-Embolization Syndrome in HCC
NCT06039280Unknown
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Sep 2023
- Primary completion
- Jul 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial in hepatocellular carcinoma (HCC) comparing NAC+Dexamethasone with NAC+Placebo (2 arms). Primary endpoint: Prevention of post-embolization syndrome at 72 hours. Status: unknown.
02
Drugs
dexamethasone
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06039280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06039280.